This confirms that prolonged CDK2 inhibition in vivo can exert sustained control of CCNE1-amplified tumors, and that rebound compensation by CDK4/6 is not present to a level sufficient to significantly restore Rb phosphorylation, cyclin A2 expression, or tumor growth. The gene discussed is CDK2; the disease is neoplasm.